Literature DB >> 26849302

CDX2: Linking Cell and Patient Fates in Colon Cancer.

Eric R Fearon1, Emina H Huang2.   

Abstract

Administering adjuvant chemotherapy to stage II colon cancer patients is controversial due to limited benefit observed for this subpopulation. Recently, Dalerba et al. (2016) identified a subgroup of stage II patients that might benefit from adjuvant chemotherapy based on lack of CDX2 expression in their cancer stem cells.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26849302      PMCID： PMC5497577          DOI： 10.1016/j.stem.2016.01.011

Source DB:  PubMed          Journal:  Cell Stem Cell        ISSN： 1875-9777            Impact factor:   24.633


  10 in total

1.  Loss of CDX2 expression is associated with poor prognosis in colorectal cancer patients.

Authors:  Jeong Mo Bae; Tae Hun Lee; Nam-Yun Cho; Tae-You Kim; Gyeong Hoon Kang
Journal:  World J Gastroenterol       Date:  2015-02-07       Impact factor: 5.742

2.  CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer.

Authors:  Piero Dalerba; Debashis Sahoo; Soonmyung Paik; Xiangqian Guo; Greg Yothers; Nan Song; Nate Wilcox-Fogel; Erna Forgó; Pradeep S Rajendran; Stephen P Miranda; Shigeo Hisamori; Jacqueline Hutchison; Tomer Kalisky; Dalong Qian; Norman Wolmark; George A Fisher; Matt van de Rijn; Michael F Clarke
Journal:  N Engl J Med       Date:  2016-01-21       Impact factor: 91.245

3.  ALCAM/CD166 is overexpressed in colorectal carcinoma and correlates with shortened patient survival.

Authors:  W Weichert; T Knösel; J Bellach; M Dietel; G Kristiansen
Journal:  J Clin Pathol       Date:  2004-11       Impact factor: 3.411

Review 4.  ALCAM/CD166: cancer-related issues.

Authors:  Ulrich H Weidle; Daniela Eggle; Stefan Klostermann; Guido W M Swart
Journal:  Cancer Genomics Proteomics       Date:  2010 Sep-Oct       Impact factor: 4.069

Review 5.  Personalizing colon cancer adjuvant therapy: selecting optimal treatments for individual patients.

Authors:  Rodrigo Dienstmann; Ramon Salazar; Josep Tabernero
Journal:  J Clin Oncol       Date:  2015-04-27       Impact factor: 44.544

Review 6.  Chemotherapy for Stage II Colon Cancer.

Authors:  Anna Varghese
Journal:  Clin Colon Rectal Surg       Date:  2015-12

7.  Relationship of CDX2 loss with molecular features and prognosis in colorectal cancer.

Authors:  Yoshifumi Baba; Katsuhiko Nosho; Kaori Shima; Ellen Freed; Natsumi Irahara; Juliet Philips; Jeffrey A Meyerhardt; Jason L Hornick; Ramesh A Shivdasani; Charles S Fuchs; Shuji Ogino
Journal:  Clin Cancer Res       Date:  2009-07-07       Impact factor: 12.531

8.  Expression of the intestinal biomarkers Guanylyl cyclase C and CDX2 in poorly differentiated colorectal carcinomas.

Authors:  Brody Winn; Rosemarie Tavares; Andres Matoso; Lelia Noble; Jacqueline Fanion; Scott A Waldman; Murray B Resnick
Journal:  Hum Pathol       Date:  2009-10-01       Impact factor: 3.466

Review 9.  Adjuvant treatment of colorectal cancer.

Authors:  Brian M Wolpin; Jeffrey A Meyerhardt; Harvey J Mamon; Robert J Mayer
Journal:  CA Cancer J Clin       Date:  2007 May-Jun       Impact factor: 508.702

10.  Phenotypic characterization of human colorectal cancer stem cells.

Authors:  Piero Dalerba; Scott J Dylla; In-Kyung Park; Rui Liu; Xinhao Wang; Robert W Cho; Timothy Hoey; Austin Gurney; Emina H Huang; Diane M Simeone; Andrew A Shelton; Giorgio Parmiani; Chiara Castelli; Michael F Clarke
Journal:  Proc Natl Acad Sci U S A       Date:  2007-06-04       Impact factor: 11.205
  10 in total
  2 in total

1.  Incorporation of CEA Improves Risk Stratification in Stage II Colon Cancer.

Authors:  Blake A Spindler; John R Bergquist; Cornelius A Thiels; Elizabeth B Habermann; Scott R Kelley; David W Larson; Kellie L Mathis
Journal:  J Gastrointest Surg       Date:  2017-03-13       Impact factor: 3.452

2.  Construction and analysis of tissue microarrays in the era of digital pathology: a pilot study targeting CDX1 and CDX2 in a colon cancer cohort of 612 patients.

Authors:  Sarah Nolte; Inti Zlobec; Alessandro Lugli; Werner Hohenberger; Roland Croner; Susanne Merkel; Arndt Hartmann; Carol I Geppert; Tilman T Rau
Journal:  J Pathol Clin Res       Date:  2017-01-13
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.